Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity—Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases

https://doi.org/10.1016/j.bmcl.2013.11.036Get rights and content

Abstract

HSP90 continues to be a target of interest for neurodegeneration indications. Selective knockdown of the HSP90 cytosolic isoforms α and β is sufficient to reduce mutant huntingtin protein levels in vitro. Chemotype-dependent binding conformations of HSP90α/β appear to strongly influence isoform selectivity. The rational design of HSP90α/β inhibitors selective versus the mitochondrial (TRAP1) and endoplasmic reticulum (GRP94) isoforms offers a potential mitigating strategy for mechanism-based toxicities. Better tolerated HSP90 inhibitors would be attractive for targeting chronic neurodegenerative diseases such as Huntington’s disease.

Section snippets

Acknowledgments

The Berkeley Center for Structural Biology is supported in part by the National Institutes of Health, National Institute of General Medical Sciences, and the Howard Hughes Medical Institute. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231.

References and notes (27)

  • L.H. Pearl et al.

    Adv. Protein Chem.

    (2001)
  • B. Baldo et al.

    J. Biol. Chem.

    (2012)
  • B. Chen et al.

    Genomics

    (2005)
  • J.M. Jez et al.

    Chem. Biol.

    (2003)
  • L. Wright et al.

    Chem. Biol.

    (2004)
  • K.L. Soldano et al.

    J. Biol. Chem.

    (2003)
  • D.E. Dollins et al.

    Mol. Cell

    (2007)
  • C.E. Stebbins et al.

    Cell

    (1997)
  • W.B. Pratt et al.

    Exp. Biol. Med.

    (2003)
  • M.J. Drysdale et al.

    Curr. Top. Med. Chem.

    (2008)
  • Y.S. Kim et al.

    Curr. Top. Med. Chem.

    (2009)
  • M.A. Biamonte et al.

    J. Med. Chem.

    (2010)
  • M. Waza et al.

    J. Mol. Med.

    (2006)
  • Cited by (48)

    • Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances

      2022, European Journal of Medicinal Chemistry
      Citation Excerpt :

      The improved physicochemical and pharmacokinetic properties suggest the further investigation of compound 103 as an anti-inflammatory agent for treating ulcerative colitis [177]. Compared to SNX-2112 (Hsp90α Ki = 4 nM; Hsp90β Ki = 6 nM; Grp94 Ki = 484 nM; Trap1 Ki = 791 nM), compound 104 (SNX-0723) showed improved selectivity for Hsp90α and Hsp90β, over Trap1 and Grp94 (Hsp90α Ki = 3 nM; Hsp90β Ki = 4 nM; Grp94 Ki = 375 nM; Trap1 Ki = 1195 nM) [69]. SNX-0723 could be absorbed by brain tissue efficiently, prevented α-Synuclein oligomerization and rescued striatal dopamine levels associated with parkinsonism [178,179].

    • 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents

      2021, European Journal of Medicinal Chemistry
      Citation Excerpt :

      In humans, Hsp90 exists as four isoforms: Hsp90α, Hsp90β, glucose-regulated protein 94 kDa (Grp94), and tumor necrosis receptor-associated protein 1 (Trap1) [14]. Hsp90α and Hsp90β are localized to the cytoplasm, whereas Grp94 resides in the endoplasmic reticulum, and Trap1 is localized within the mitochondria [15]. Most Hsp90 inhibitors are pan-inhibitors that target both cytosolic isoforms (Hsp90α and Hsp90β) [16].

    • Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery

      2020, Acta Pharmaceutica Sinica B
      Citation Excerpt :

      The pan-HSP90 inhibitors cannot induce the extended α-helix conformation, so they exhibit similar activity against HSP90, GRP94 and TRAP143. While, based on the sequential difference of HSP90α/β, structural insights for the design of inhibitors with improved HSP90α/β selectivity have been provided44. TAS-116, an HSP90α/β selective inhibitor which was developed through fragment-based drug design by Taiho Pharmaceutical Co., Ltd., has been entered into clinical trials.

    View all citing articles on Scopus
    View full text